Market News & Trends
New Lipid Facility at Evonik’s Site in Hanau to Produce Clinical & Launch Quantities of Lipids for Innovative Medicines
Evonik is building a new cGMP facility to manufacture lipids for clinical development and launch of innovative medicines. The new cGMP lipid launch facility is located in….
Context Therapeutics & The Menarini Group Announce Clinical Trial Collaboration & Supply Agreement
Context Therapeutics Inc. and The Menarini Group recently announced a clinical trial collaboration and supply agreement for Menarini’s oral selective estrogen receptor degrader (SERD), elacestrant.…
Curia Appoints Niall Condon to Lead Manufacturing
Curia recently announced the appointment of Niall Condon as President of its Manufacturing Division, with immediate effect. Condon will drive growth and be responsible for…
Enteris BioPharma Announces Acceptance of Abstract for Oral Presentation at ASRM 2022 Scientific Congress & Expo
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq:…
Verrica Pharmaceuticals Announces Start of Phase 3 Trial for the Treatment of Molluscum Contagiosum
Verrica Pharmaceuticals Inc. recently announced Torii Pharmaceutical Co., Ltd. dosed the first patient in its Phase 3 trial of VP-102 (referred to as TO-208 in…
Avalo Therapeutics Transfers Anti-IL-18 Antibody to Apollo Therapeutics
Avalo Therapeutics, Inc. and Apollo Therapeutics Group Limited have entered into a worldwide, exclusive license agreement granting rights to Apollo to research, develop, manufacture and commercialize….
SCHOTT Establishes Stand-Alone Company for its Pharma Business to Promote Further Growth
SCHOTT has legally established a stand-alone company for its pharma business to advance its growth strategy. As a pioneer in pharma drug containment and system solutions, the international technology….
CymaBay Completes Enrollment for the RESPONSE Global Phase 3 Study Evaluating Seladelpar for Patients With Primary Biliary Cholangitis
CymaBay Therapeutics, Inc. recently announced the completion of enrollment for RESPONSE, a global Phase 3 study evaluating seladelpar for patients with Primary Biliary….
Vaxxinity Presents Preclinical Data on Tau Vaccine Candidates
Vaxxinity, Inc. recently presented new preclinical data on vaccine candidates targeting aberrant forms of the Tau protein for Alzheimer’s disease (AD) during a poster session at the….
Akari Therapeutics Narrows Pipeline Focus
Akari Therapeutics, Plc recently announced it is prioritizing two pipeline programs. Cash and resources will be reallocated to the Phase 3 clinical trial of nomacopan…
Agenus Announces First Patient Dosed in Phase 1 Study of AGEN1571 in Advanced Solid Tumors
Agenus Inc. recently announced the first patient has been dosed in the Phase 1 study of AGEN1571 in advanced solid tumors. The dose-escalation and expansion…
Kymanox Announces First Fellow Position
Kymanox Corporation recently announced Izi Bruker, PhD, MPH, ASQ has been named as the first Fellow of Kymanox. This highly distinguished honor is reserved for…
SciSparc Signs Clinical Trial Agreement With Yale University to Conduct Phase 2b Trial in Tourette Syndrome
SciSparc Ltd. recently announced the addition of another site of excellence, the Yale Child Study Center at Yale University, to its Phase 2b clinical trial…
Starton Therapeutics Reports Positive Results From Phase 1 Study Evaluating Continuous Delivery Lenalidomide
Starton Therapeutics Inc. recently announced positive results from high-level data from its Phase 1 study of STAR-LLD, evaluating the pharmacokinetics (PK) and safety of the company’s continuous delivery….
Nanoform & Pharmanovia to Breathe New Life Into Iconic Medicines
Nanoform Finland Plc. recently announced it has partnered with Pharmanovia, a fast-growing specialty pharma business with a portfolio of over 20 branded drugs in 140 markets…..
TFF Pharmaceuticals Expands R&D Operations With New Austin Facility
TFF Pharmaceuticals, Inc. recently announced a significant expansion of its R&D operations through the lease of a new research and development facility located in Austin,…
Xequel Bio Announces Positive Results From Phase 1b Study for Novel aCT1 Ophthalmic Solution
Xequel Bio, Inc. recently announced positive results from its Phase 1b clinical trial with iNexin (aCT1 ophthalmic solution) for the treatment of corneal injury in…
US Alliance Pharma Acquires UK-Based LGC’s Drug Development Solutions Business
Alliance Pharma recently closed on the purchase of Drug Development Solutions (DDS) from LGC. Ampersand Capital Partners, a global healthcare private equity firm, and KKR & Co. Inc., a leading global investment….
Comera Life Sciences Announces Favorable Preclinical Topline Safety Results of Lead SQore Excipient
Comera Life Sciences Holdings, Inc. recently announced favorable topline results from its recently completed SEQURUS-1 study. The results of this preclinical study provide supportive evidence…
Evonik Now Offers Enteric-Protected Ready-to-Fill Capsules – EUDRACAP- in IPEC-GMP Quality
Evonik’s EUDRACAP enteric easy-to-handle capsules are now globally available produced under IPEC-GMP. Launched last year, EUDRACAP enteric are….
